Do You Actually Need to Increase Your Wegovy Dose?

The misconception: dose increases are automatic after four weeks

Plenty of people arrive at their four-week mark expecting to move up simply because the calendar says so. It is easy to see why, the titration schedule in Wegovy's leaflet reads like a staircase with fixed steps. But those steps describe the earliest a prescriber can move you up, not a programme that runs regardless of what is happening to you.

The question of whether a Wegovy dose increase is clinically right involves at least two things: how much side-effect burden the current dose is causing, and whether your body is already responding with meaningful weight loss. A patient still managing daily nausea on 0.5 mg is not a strong candidate for 1.0 mg next week. That is not a failure, it is exactly how the prescriber is supposed to use the schedule. The NHS medicines guidance for semaglutide notes that the titration steps exist to manage tolerability, not to guarantee progression speed. Staying at a lower dose longer is sometimes the safer, more effective long-term choice.

This also means that if you are losing weight steadily and feeling well, your prescriber might reasonably question whether going higher is necessary at all. Higher doses carry a higher side-effect likelihood; there is no clinical prize for reaching 2.4 mg quickly.

What your prescriber actually weighs up before agreeing to increase

Before any step up, a prescriber will want to know how you have been on the current dose. The practical checklist tends to cover: severity and frequency of nausea, vomiting, diarrhoea or constipation; whether those effects are settling or still acute; your current weight trend; and whether you have been able to eat and stay hydrated adequately.

For people working through the mid-range doses, the GI side-effect pattern often peaks in the first week or two after each step and then quietens. If it has not quietened, increasing again risks compounding the problem. The NHS's clinical guidance makes clear that an increase should not happen while tolerability remains poor at the current level.

There is also a practical evidence point worth knowing: NHS guidance on semaglutide describes the full titration pathway and sets out that the prescriber decides the pace. NICE's appraisal of semaglutide for weight management, TA875, frames the medicine as part of a supervised programme, the clinical relationship is part of what makes the treatment work. Trying to self-direct the schedule around that relationship tends not to end well.

Honestly, if you are sitting at home Googling whether you should go up a dose, that feeling is understandable. Progress can feel slow, and the urge to do something about it is real. A conversation with your prescriber (not a dose change based on impatience) is the productive move here.

When staying on the same dose is actually the right answer

There are legitimate clinical reasons to hold at a given dose for longer than four weeks, and sometimes to stay there indefinitely. These include ongoing side effects that have not resolved, a complicating health event (illness, surgery), a period of reduced eating for unrelated reasons, or (and this is worth saying plainly) already achieving good results at the current level.

The timing of a Wegovy increase is not one-size-fits-all. Some patients reach a maintenance dose lower than 2.4 mg and stay there for the duration of treatment because the weight response is satisfactory and the tolerance is good. Chasing the maximum dose for its own sake is not clinically indicated. If you want to understand more about the full Wegovy dose range and what each step represents, that context helps frame these conversations.

One practical point on the new 7.2 mg pen: the MHRA approved a dedicated single-dose 7.2 mg pen in April 2026 for adults with a BMI of 30 or above. This higher dose is not a routine step for everyone, it is an option where clinical assessment supports it, and it comes with its own titration process starting at 0.25 mg.

How to have the dose conversation with your prescriber, and what to do if you are unsure

Come prepared with specifics rather than a general sense that things could be better. What side effects have you had, and are they improving or static? What does your weight trend look like over the past four weeks? Have you been eating and drinking normally? That concrete picture lets a prescriber make a real decision rather than a guessed one.

At nume, a named GPhC-registered prescriber reads your answers before any repeat or dose change, not software, not an automated system. If the evidence supports an increase, it moves forward. If it does not, you will hear why, with an explanation rather than a rejection slip. You can find out more about the clinical oversight behind our service on the our clinical team page. If cost is part of the picture as you think through treatment, the Wegovy cost page sets out what private treatment typically involves. When you are ready to talk through your specific situation, start your free consultation and a prescriber will review it the same day.